Ledipasvir/SofosbuvirOther Names: Harvoni Drug Class: Opportunistic Infections and Coinfections
What is ledipasvir/sofosbuvir?
Ledipasvir/sofosbuvir is a prescription medicine approved by the U.S. (FDA) for the treatment of chronic (lasting a long time) C (HCV) infection in adults and in children 12 years of age and older or weighing at least 77 pounds (35 kg). The medicine combines two drugs (ledipsavir and sofosbuvir) in a single pill.
HCV is an of HIV. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems. To learn more about opportunistic infections, read the What is an Opportunistic Infection? fact sheet.
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the sofosbuvir to treat chronic HCV infection in people also infected with HIV.
In addition to recommendations for the medicine's use in treating chronic HCV infection, the guidelines and the guidance include recommendations on the of ledipasvir/sofosbuvir to treat acute HCV infection in HIV-infected individuals. Off-label use refers to use of an FDA-approved medicine in a manner different from that described on the medicine label. Good medical practice and the best interests of a patient sometimes require that a medicine be used off-label.
What should I tell my health care provider before taking ledipasvir/sofosbuvir?
Before taking ledipasvir/sofosbuvir, tell your health care provider:
- If you are allergic to ledipasvir/sofosbuvir or any other medicines.
- About any medical conditions you have or have had, for example, or liver problems.
- If you take a medicine called tipranavir.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
- If you are pregnant or plan to become pregnant. Whether ledipasvir/sofosbuvir can harm an unborn baby is unknown. Ledipasvir/sofosbuvir should be used during pregnancy only if the potential benefit justifies the potential risk to the unborn baby. Talk to your health care provider about possible risks with taking ledipasvir/sofosbuvir when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you are infected with HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Ledipasvir/sofosbuvir may affect the way other medicines or products work, and other medicines or products may affect how ledipasvir/sofosbuvir works. Ask your health care provider if there are interactions between ledipasvir/sofosbuvir and the other medicines you take.
How should I take ledipasvir/sofosbuvir?
Take ledipasvir/sofosbuvir according to your health care provider’s instructions. Your health care provider will tell you how much ledipasvir/sofosbuvir to take and when to take it. Before you start ledipasvir/sofosbuvir and each time you get a refill, read any printed information that comes with your medicine.
How should ledipasvir/sofosbuvir be stored?
- Store ledipasvir/sofosbuvir at room temperature, 68°F to 77°F (20°C to 25°C), below 86°F (30°C).
- Keep ledipasvir/sofosbuvir in its original container.
- Do not use ledipasvir/sofosbuvir if the original seal over the container opening is broken or missing.
- Throw away ledipasvir/sofosbuvir that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep ledipasvir/sofosbuvir and all medicines out of reach of children.
Where can I find more information about ledipasvir/sofosbuvir?
More information about ledipasvir/sofosbuvir is available:
- Recommendations on the HIV-related use of ledipasvir/sofosbuvir, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by CDC, NIH, and IDSA-HIVMA
- Recommendations on the HIV-related uses of ledipasvir/sofosbuvir, from the Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected with Hepatitis C Virus, prepared by AASLD, IDSA, and IAS-USA
- Ledipasvir/sofosbuvir-related research studies, from the AIDSinfo database of study summaries
The above Patient Version drug summary is based on the following FDA label(s): Tablet (film coated).
Last Reviewed: May 3, 2017